Zoonotic Disease Treatment Market By Treatment Type (Antimicrobial Therapies [Antibacterial Agents, Antiviral Formulations, Antifungal Medications, Antiparasitic Compounds], Immunological & Prophylactic Interventions [Vaccines, Immune Globulins, Monoclonal Antibodies], Supportive & Intensive Care, Surgical & Interventional Procedures), By Disease Type (Rabies, Lyme Disease, Campylobacteriosis, Brucellosis, Leptospirosis, Ebola Virus Disease, Avian Influenza, Hantavirus, Echinococcosis, Other Zoonotic Diseases), By End User (Hospitals & Clinics, Specialty & Infectious Disease Centers, Public Health & Vaccination Centers, Emergency & Critical Care Centers, Government & Strategic Stockpile Agencies), By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Zoonotic Disease Treatment Market: Multi-Pathogen Therapeutics, Post-Exposure Biologics, Intensive Care, and Government Procurement Shape Commercial Demand

The Global Zoonotic Disease Treatment Market was valued at USD 43.60 billion in 2025 and is projected to reach USD 66.87 billion by 2032, expanding at a CAGR of 6.3% during 2026–2032.

 

Treatment for zoonotic diseases depends on the pathogen involved. Bacterial infections are treated with appropriate antibiotics, while viral infections may require supportive care, antivirals, or urgent post-exposure vaccination and immune globulin, particularly for rabies. Fungal infections are managed with topical or oral antifungal medicines, and parasitic infections are treated with antiparasitic drugs; severe cyst-related disease may sometimes require surgery.

 

Management also focuses on preventing further transmission. Treating infected animals when appropriate can reduce reinfection risks. Important preventive measures include handwashing, cleaning bites or scratches promptly, handling food safely, and avoiding raw meat or unpasteurized dairy products.

 

Anyone with a suspected zoonotic exposure should seek medical care promptly, as accurate diagnosis is essential for choosing the correct treatment and determining whether emergency preventive therapy is needed.

 

FDA-approved pathogen-specific drugs represent a high-value segment of the market, with Inmazeb (Regeneron) becoming the first FDA-approved treatment for Zaire ebolavirus in October 2020, followed by Ebanga (Ridgeback Biotherapeutics) in December 2020; both are monoclonal antibody therapies designed to neutralize the Ebola virus and improve survival when administered early, and their use is largely concentrated in outbreak situations where demand is driven not by routine prescribing but by government procurement, strategic stockpiling, and rapid deployment capabilities.

 

The treatment population spans several zoonotic diseases rather than a single patient group. In the U.S., about 476,000 people are treated for Lyme disease each year, while Campylobacter leads to around 1.9 million illnesses and 13,000 hospitalizations. Roughly 100,000 Americans receive rabies vaccination after potential exposure annually. Globally, over 29 million people receive rabies vaccines each year, alongside an estimated 2.1 million brucellosis cases and 1.03 million leptospirosis cases.

 

How Do Antimicrobial Therapies Form the Recurring Treatment Base?

Antimicrobial therapy supplies the broadest recurring pharmaceutical demand within zoonotic disease treatment because bacterial, viral, fungal, and parasitic zoonoses require different pathogen-targeted drugs. This category is commercially less dependent on emergency stockpiling than rabies or Ebola biologics, but utilization varies widely according to severity, resistance patterns, treatment duration, relapse risk, and whether therapy can be delivered through inexpensive generic products.

 

Why Do Antibacterial Agents Generate High Treatment Volumes?

Antibacterial agents account for a substantial share of recurring prescriptions because Lyme disease, brucellosis, Q fever, leptospirosis, plague, tularemia, and several animal-associated wound infections are managed with antimicrobial drugs. Doxycycline, beta-lactams, macrolides, fluoroquinolones, aminoglycosides, and other agents can occupy different positions depending on the pathogen and clinical presentation.

Lyme disease illustrates the scale of the treated base. More than 89,000 cases were reported to CDC in 2023, but claims and other clinical-data methods suggest approximately 476,000 people may be diagnosed and treated annually. That distinction matters commercially because prescription utilization is tied more closely to clinical diagnosis and treatment than to nationally reported surveillance cases.

Campylobacter produces an even larger infection burden. A 2025 CDC Emerging Infectious Diseases analysis estimated 1.9 million domestically acquired U.S. illnesses and approximately 13,000 hospitalizations. Most infections do not require antibiotics, so incidence cannot be converted directly into pharmaceutical volume; treatment is concentrated among severe cases and higher-risk patients. This creates substantial but clinically filtered antibiotic demand rather than treatment of every infection.

Brucellosis creates greater drug utilization per treated patient because therapy is prolonged and normally uses more than one agent. CDC states that infections caused by major Brucella species are typically managed with doxycycline plus rifampin for at least six weeks, with alternative regimens required in selected complicated infections and resistant strains. An estimated 2.1 million new human cases occur globally each year, with Africa and Asia carrying much of the burden. Long treatment duration, combination therapy, and relapse risk make brucellosis commercially distinct from short-course infections.

Early antibiotic availability can also alter outcomes dramatically in severe zoonoses. CDC treatment guidance reports that untreated bubonic plague historically carries a fatality rate of approximately 66%, compared with about 13% with antimicrobial treatment. The low absolute incidence of plague limits prescription volume, but the difference illustrates why governments and hospitals must retain immediate access to effective antimicrobials for rare zoonotic emergencies.

 

How Do Antiviral Formulations Support Outbreak-Responsive Demand?

Antiviral demand is more episodic because many viral zoonoses either lack pathogen-specific therapy or produce unpredictable outbreaks. Influenza antivirals are commercially relevant during zoonotic influenza events because treatment can be initiated rapidly when animal-to-human transmission is suspected, while public-health systems may also hold inventories before patient volumes rise.

For avian influenza A(H5N1), WHO's July 2026 update recorded 485 laboratory-confirmed human cases since 2003, including 320 deaths, producing a historical reported case-fatality ratio of approximately 66%. This figure reflects detected laboratory-confirmed cases rather than the fatality risk of all infections, but it explains the intense clinical and public-health focus on rapid treatment when human cases appear.

Antiviral manufacturers therefore participate in a market where purchasing can be triggered by livestock or poultry outbreaks, occupational exposures, hospital preparedness, and government inventories rather than only by confirmed human infections.

 

Where Do Antifungal Therapies Fit Within the Market?

Fungal zoonoses represent a smaller and more fragmented treatment opportunity than bacterial infections or rabies PEP. Dermatophyte infections such as animal-associated ringworm can require topical or systemic antifungal treatment, depending on infection site and severity. Commercial demand is concentrated in outpatient and dermatology channels and is generally characterized by established generic products rather than high-value emergency biologics.

The strategic value of this category lies in its recurring community-treatment volume rather than large individual treatment costs. Veterinary exposure, household transmission, occupational contact with animals, and treatment-resistant or extensive infections can extend utilization beyond basic topical therapy.

 

Why Do Antiparasitic Drugs Generate Longer Treatment Pathways?

Parasitic zoonoses can require extended pharmacologic treatment and, in some cases, a combination of drugs and procedures. Agents such as albendazole and praziquantel are used across selected helminthic infections, while therapy for diseases such as echinococcosis depends heavily on parasite location, cyst characteristics, and complication risk.

WHO's 2025 cystic echinococcosis treatment guidelines formalized a stage-specific approach that can involve antiparasitic therapy, percutaneous intervention, surgery, or observation rather than a single standardized regimen. The market opportunity therefore extends beyond drug volume into hospital procedures, imaging follow-up, surgery, and specialist care.

 

Why Are Immunological and Prophylactic Interventions Strategically Important?

Immunological interventions generate some of the highest-value revenue per exposure within the zoonotic disease treatment market. Unlike conventional anti-infectives, vaccines, immune globulins, and monoclonal antibodies may need to be administered before clinical disease develops or immediately after exposure, making rapid availability an essential purchasing criterion.

 

Why Does Passive Immunization Create a High-Value Rabies Segment?

Human rabies immune globulin provides pre-formed antibodies immediately after a qualifying exposure in previously unvaccinated patients while active vaccine-induced immunity develops. CDC's current PEP guidance combines wound care, HRIG, and a multi-dose rabies vaccine series for previously unvaccinated individuals.

This pathway creates a concentrated biologics market because HRIG is required urgently, frequently through emergency departments or hospitals, and cannot simply be replaced by routine oral therapy. Manufacturers therefore compete around plasma sourcing, biologic manufacturing, inventory availability, hospital access, distribution, and reimbursement.

 

Why Do Rabies Vaccines Create Exceptionally Large PEP Volume?

WHO reports that more than 29 million people worldwide receive human rabies vaccine every year, making rabies PEP one of the largest recurring immunological interventions associated with zoonotic exposure.

CDC states that PEP administered after exposure is nearly 100% effective when received appropriately before disease develops. This shifts spending toward rapid exposure assessment, vaccine availability, HRIG, wound care, and completion of the vaccination course.

Dose-sparing strategies can materially alter procurement economics. WHO has reported that intradermal administration can reduce the volume and cost of cell-culture rabies vaccine by approximately 60%–80% compared with intramuscular approaches, improving coverage in high-burden settings.

 

How Are Monoclonal Antibodies Changing High-Risk Zoonotic Treatment?

Monoclonal antibodies have introduced highly pathogen-specific therapy into zoonotic diseases that historically depended mainly on supportive care. Inmazeb and Ebanga target Zaire ebolavirus glycoprotein and are FDA-approved for infection caused by Zaire ebolavirus.

WHO notes that average Ebola disease case fatality across past outbreaks has been approximately 50%, with substantial variation between outbreaks. Early intensive supportive care improves survival, and WHO recommends monoclonal-antibody treatment for Ebola virus disease caused by Zaire ebolavirus.

Commercially, these medicines operate very differently from high-volume chronic therapies, with demand concentrated in outbreak response, treatment centers, government procurement, and strategic stockpiles.

 

Why Does Rabies PEP Represent One of the Clearest High-Value Biologics Markets?

Rabies demonstrates how prevention after exposure can generate significant treatment spending despite very low incidence of clinical disease in well-resourced countries. Once symptomatic disease develops, survival is exceedingly rare, so the economically relevant patient funnel begins with bites and suspected exposure rather than diagnosed clinical rabies.

In the United States, approximately 100,000 people receive rabies vaccination following a potential exposure each year, even though human rabies deaths remain rare.

Kamada's commercial results demonstrate the value concentrated within the HRIG category. The company reported USD 53.6 million in 2025 KEDRAB sales to Kedrion, compared with USD 50.0 million in 2024 and USD 32.8 million in 2023. Kamada attributed the 2025 increase partly to stronger U.S. demand. Its ex-U.S. KAMRAB revenue also increased to USD 17.2 million in 2025, from USD 11.7 million in 2024.

 

Fluid and Hemodynamic Support in Treatment Utilization

Severe gastrointestinal zoonoses can require intravenous fluid and electrolyte replacement when dehydration becomes clinically important. More invasive bacterial disease can progress to sepsis or shock, increasing utilization of hospital fluids, vasopressors, antimicrobial combinations, laboratory monitoring, and critical-care capacity.

Ebola provides a more extreme example. WHO states that early intensive supportive care, including rehydration and symptomatic management, improves survival even when pathogen-specific monoclonal antibodies are available.

 

Why Hantavirus Creates High Critical-Care Intensity Despite Low Patient Volume?

Hantavirus pulmonary syndrome has no routinely established pathogen-specific curative therapy, making rapid respiratory and hemodynamic support central to management. CDC states that approximately 38% of patients who develop severe respiratory symptoms may die, while advanced cardiopulmonary support can be required in critically ill patients.

CDC has also reported that early extracorporeal membrane oxygenation in selected patients has achieved survival of around 80% in reported experience. Although patient volumes are small, such cases generate high treatment intensity and substantial per-patient hospital resource consumption.

 

Why Do Surgical and Interventional Procedures Remain Necessary in Selected Zoonoses?

Some zoonotic diseases produce structural abnormalities, tissue destruction, or contaminated wounds that cannot be managed adequately through systemic medicine alone. These conditions extend market value beyond pharmaceuticals into surgery, interventional radiology, hospital consumables, anesthesia, imaging, and wound-care products.

 

How Does Echinococcosis Create Surgical and Interventional Demand?

Hydatid cysts caused by echinococcosis can require surgery or percutaneous intervention when cyst location, stage, complications, or mass effect make drug-only treatment unsuitable. WHO's 2025 guidance recognizes several management approaches, including antiparasitic medicines, percutaneous procedures, surgery, and observation according to cyst characteristics.

The disease therefore creates a multi-component treatment pathway in which albendazole may be used before, after, or instead of intervention depending on the case.

 

How Are Treatment Outcomes Influencing Therapy Selection?

In zoonotic disease treatment, commercial value is often driven more by how early therapy improves outcomes, treatment urgency, and duration than by disease prevalence alone. For example, plague shows a major survival improvement with antibiotics (from about 66% untreated fatality to ~13% with treatment), making rapid drug access critical despite low case numbers. Rocky Mountain spotted fever similarly requires immediate doxycycline, as delays can lead to severe outcomes with a 5%–10% fatality rate in severe cases, particularly affecting children. Brucellosis drives value through long treatment courses, typically at least six weeks of combination therapy, with complicated cases requiring even longer regimens. Together, these examples show that rare but severe or prolonged infections can generate higher per-case treatment value than more common, short-course infections.

 

How Are Leptospirosis and Climate-Sensitive Outbreaks Creating Episodic Antibiotic Demand?

Leptospirosis contributes approximately 1.03 million cases and 58,900 deaths annually worldwide, with the largest burden concentrated in tropical environments.

Its treatment market can rise rapidly following environmental disruption. During January–July 2025, the Philippines recorded 3,037 leptospirosis cases, including 1,114 shortly after the rainy season began. Hospitals subsequently reported capacity pressure during the surge.

This creates a procurement problem different from stable outpatient prescribing, requiring hospitals and health agencies to maintain sufficient inventories of antibiotics, fluids, dialysis capability, and critical-care resources before outbreaks peak.

 

How Are H5 Avian Influenza and Ebola Creating Stockpile-Driven Revenue?

Emerging zoonotic viruses create a strategically important treatment market because governments may purchase therapies before large clinical caseloads emerge.

For A(H5N1), WHO reported 485 laboratory-confirmed human infections and 320 deaths cumulatively through July 2026. The high historical fatality ratio among detected cases keeps antiviral readiness and rapid access to treatment high on public-health agendas.

Ebola operates through an even more specialized preparedness model. FDA-approved Inmazeb and Ebanga must be available when outbreaks occur, yet maintaining conventional commercial inventory for an unpredictable disease is economically difficult.

Regeneron's 2025 annual report disclosed that the company donated up to 500 doses of its Ebola medicine to WHO for use in countries considered most at risk, highlighting reliance on global health partnerships rather than retail distribution.

 

How Do Reimbursement and Public Procurement Influence Treatment Access?

The zoonotic treatment market includes both insurance-reimbursed therapy and public-health procurement. Antibiotics typically follow standard reimbursement pathways, while vaccines, immune globulins, monoclonal antibodies, and outbreak countermeasures rely more on government purchasing and stockpiles.

Rabies PEP is particularly sensitive to access because treatment must begin immediately after exposure, requiring reliable hospital availability of HRIG and vaccine.

In lower- and middle-income settings, procurement becomes central due to affordability constraints, making tender pricing, supply reliability, and public-health financing key determinants of access.

Latin America illustrates this dynamic, with PAHO reporting approximately 11.4 million canine rabies vaccine doses and 1.3 million human rabies vaccine and immunoglobulin products procured in 2024.

 

Which Companies Are Shaping Competition in Zoonotic Disease Treatment?

The competitive landscape is fragmented because companies operate across different therapeutic categories rather than a single market.

Kamada’s Positioning
Kamada is a key player in rabies biologics through KEDRAB and KAMRAB. KEDRAB sales reached USD 53.6 million in 2025, while KAMRAB generated USD 17.2 million, reflecting sustained demand for rabies immune globulin products.

Bavarian Nordic Positioning
Bavarian Nordic focuses on vaccines, including Rabipur/RabAvert, with travel-health revenue rising 24% to DKK 1.386 billion in H1 2025, driven by rabies and tick-borne encephalitis vaccines.

Regeneron Positioning
Regeneron’s Inmazeb targets Ebola virus disease, with demand concentrated in outbreak response and government procurement rather than routine prescribing.

Emergent BioSolutions Positioning
Emergent BioSolutions focuses on government countermeasures, including BioThrax, CYFENDUS, ANTHRASIL, raxibacumab, and Ebanga, with demand driven by stockpiles and biodefense preparedness.

 

How Are Different Global Regions Shaping the Market?

North America accounts for 37.0% of the market, valued at USD 16.13 billion, and is projected to grow at a CAGR of 5.9%. It combines high Lyme disease treatment volumes, Campylobacter infections, and approximately 100,000 annual rabies PEP cases, alongside strong biologics and government procurement demand.

Europe accounts for 28.0% of the market, valued at USD 12.21 billion, and is projected to grow at a CAGR of 5.7%. Demand is driven by surveillance-based detection of brucellosis, leptospirosis, hepatitis E, and animal-associated infections, alongside travel vaccination and outbreak preparedness.

Asia-Pacific accounts for 24.0% of the market, valued at USD 10.46 billion, and is projected to grow at a CAGR of 7.8%. It is driven by high rabies burden, millions of animal bites, leptospirosis outbreaks, and large-scale public procurement of vaccines and antibiotics.

Latin America accounts for 7.0% of the global market, valued at approximately USD 3.05 billion, and is projected to grow at a CAGR of 6.6%, while having substantially reduced dog-mediated rabies through vaccination and public-health programs, but continuing exposure means human PEP procurement remains necessary.

PAHO reported that Member States procured approximately 1.3 million human rabies vaccine and immunoglobulin products during 2024, alongside 11.4 million canine rabies vaccine doses.

Africa carries a particularly high unresolved rabies burden, with WHO regional analysis estimating approximately 21,476 human deaths per year in Africa from dog-mediated rabies, accounting for more than one-third of the estimated global burden in the cited analysis, while the broader Middle East & Africa region represents about 4.0% of the global market, valued at approximately USD 1.74 billion, and is projected to grow at a CAGR of 6.9%.

Brucellosis further expands antimicrobial requirements. CDC-supported global analysis identifies Africa and Asia as carrying most of the world's estimated 2.1 million annual brucellosis cases.

 

What Will Determine Commercial Growth Through 2032, According to Analysts?

The zoonotic disease treatment market is driven by four main areas: antibiotics, vaccines and immune globulins, advanced biologics for outbreaks, and hospital-based supportive care.

Antibiotics account for the largest treatment volume, supported by high case numbers such as Lyme disease in the U.S. (hundreds of thousands of treated cases annually) and millions of global infections from diseases like Campylobacter, brucellosis, and leptospirosis.

Rabies is a key biologics segment, with over 29 million people receiving rabies vaccination each year worldwide. Demand is reinforced by products like KEDRAB, which has shown steady sales growth, and Bavarian Nordic’s rabies vaccine portfolio, highlighting consistent commercial uptake.

Outbreak-related diseases such as Ebola, H5N1, and anthrax create lower routine demand but drive strong government spending on vaccines, antibodies, and stockpiles due to preparedness needs.

Regional demand varies: North America focuses on high-value biologics, Asia-Pacific leads in volume and public procurement, Europe has steady surveillance-driven demand, Latin America maintains strong rabies PEP programs, and Africa faces the highest unmet burden and access challenges.

Overall, growth depends on strong manufacturing, vaccine and biologics supply, government contracts, and outbreak readiness. The market is projected to grow from USD 43.60 billion in 2025 to USD 66.87 billion by 2032, at a CAGR of 6.3%.

 

Zoonotic Disease Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 43.60 Billion
Revenue Forecast in 2032	USD 66.87 Billion
Overall Growth Rate	CAGR of 6.3% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Disease Type, By End User, By Geography
By Treatment Type	Antimicrobial Therapies [Antibacterial Agents, Antiviral Formulations, Antifungal Medications, Antiparasitic Compounds], Immunological & Prophylactic Interventions [Vaccines, Immune Globulins, Monoclonal Antibodies], Supportive & Intensive Care, Surgical & Interventional Procedures
By Disease Type	Rabies, Lyme Disease, Campylobacteriosis, Brucellosis, Leptospirosis, Ebola Virus Disease, Avian Influenza, Hantavirus, Echinococcosis, Other Zoonotic Diseases
By End User	Hospitals & Clinics, Specialty & Infectious Disease Centers, Public Health & Vaccination Centers, Emergency & Critical Care Centers, Government & Strategic Stockpile Agencies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising zoonotic disease outbreaks, increasing antimicrobial and vaccine demand, government preparedness programs and strategic stockpiling, growing need for post-exposure prophylaxis, expansion of infectious disease surveillance systems, and higher demand for pathogen-specific biologics and intensive care support
Customization Option	Available upon request